今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001076809-20-000123 Size: 5 KB 网页链接
$Trident(TDAC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001076809-20-000115 Act: 34 Size: 59 KB 网页链接
$Trident(TDAC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-20-020932 Act: 34 Size: 2 MB 网页链接
$Trident(TDAC)$ PRE 14A Other preliminary proxy statements Accession Number: 0001213900-20-019566 Act: 34 Size: 225 KB 网页链接
$Trident(TDAC)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001393825-20-000124 Size: 9 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001393825-20-000123 Size: 9 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 1.01, 5.03, 5.07, and 9.01 Accession Number: 0001213900-20-013887 Act: 34 Size: 43 KB 网页链接
$Trident(TDAC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-20-013789 Act: 34 Size: 23 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-20-013788 Act: 34 Size: 23 KB 网页链接
$Trident(TDAC)$ DEF 14A Other definitive proxy statements Accession Number: 0001213900-20-012703 Act: 34 Size: 147 KB 网页链接